Biotech and Pharmaceuticals Pharmaceuticals

More

  • These are America's 5 most expensive prescription drugs

    Prescription drug prices have soared, often exceeding US average annual income. These are the five most expensive.

  • The newest iPad Pro, with a smaller 9.7-inch screen, is introduced at an Apple Event in Cupertino, CA on March 21, 2016.

    A Cleveland Clinic program lets patients schedule a "virtual visit" with a doctor using a tablet, smartphone, or desktop.

  • biotech pharmaceuticals

    Shares of Ziopharm Oncology fell 14 percent Friday after a cancer patient died soon after being injected with the company's experimental therapy.

  • WASHINGTON/ NEW YORK, July 15- Herbalife Ltd agreed to pay $200 million and change the way it does business to avoid being labeled a pyramid scheme by regulators, a blow to hedge fund manager Bill Ackman who for years has been betting against the dietary supplements maker. Shares of Herbalife jumped more than 20 percent after the settlement was made public and the...

  • WASHINGTON/ NEW YORK, July 15- Herbalife Ltd agreed to a $200 million settlement with U.S. regulators on Friday, under which the dietary supplements maker will change the way it does business and avoid being labeled a pyramid scheme, a blow to hedge fund manager Bill Ackman who for years has been betting against the company. The Los Angeles- based company's shares...

  • July 15- Herbalife Ltd said it would settle with the U.S. Federal Trade Commission for $200 million to avoid being labeled a pyramid scheme, a blow to hedge fund manager Bill Ackman who for years has been betting against the dietary supplements maker. Ackman's Pershing Square Capital Management unveiled a $1 billion short bet against the company in 2012..

  • NEW YORK— Federal regulators closed an investigation of the multinational, nutritional supplements company Herbalife, which has for years been dogged by accusations that it was run as an elaborate pyramid scheme. Though Herbalife was ordered to restructure its U.S. operations and pay a $200 million settlement Friday, it avoided being classified by the U.S. as...

  • NYSE end of day, after hours

    Check out the companies making headlines after the bell Thursday.

  • Did Shkreli kill the biotech rally?

    CNBC's Meg Tirrell reports the latest on Martin Shkreli's legal battle and the "Fast Money" traders weigh in on the biotech sector.

  • Opening Bell, July 14, 2016

    Today's bell ringers are Jung-ho Shin, Chief Global Officer of Line Corporation, at the NYSE; and Jeffrey Bacha, Chairman & CEO of Delmar Pharmaceuticals, at the Nasdaq.

  • July 13- Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. Novartis tested the drug, GP2015, in patients with plaque psoriasis but if approved by the FDA, it would be approved for all...

  • July 13- Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade, a bit faster than the past two years, due to an aging population, rising medical prices and faster economic growth, according to updated projections from the federal government released on Wednesday. The annual growth of health expenditures...

  • July 13- Andrew Left, who runs short-selling firm Citron Research, is planning to take a short position in Valeant Pharmaceuticals International Inc again, TheStreet reported. Left's comments come a day after Sequoia Fund, which once was Valeant's largest shareholder, said it exited its position in the embattled Canadian drugmaker last month.

  • July 13- Andrew Left, who runs short-selling firm Citron Research, is planning to take a short position in Valeant Pharmaceuticals International Inc again, TheStreet reported. Left's comments come a day after Sequoia Fund, which once was Valeant's largest shareholder, said it exited its position in the embattled Canadian drugmaker last month.

  • July 13- Allergan Plc said it extended the deadline to close a deal to sell its generic business to Teva Pharmaceutical Industries Ltd by three months to October. Israel's Teva and Allergan also agreed to reduce the cash consideration to be paid by $221 million and added Actonel and Carafate to the list of excluded products, Allergan said in a regulatory filing...

  • July 13- Ruane, Cunniff& Goldfarb Inc, the investment firm that runs the Sequoia Fund and once the largest shareholder of Valeant Pharmaceuticals International Inc, said it exited its position in the embattled Canadian drugmaker by mid-June. Valeant has been under intense scrutiny for its business and accounting practices, sending its shares plummeting 91...

  • July 13- Allergan Plc said the closing of a deal to sell its generic business to Teva Pharmaceutical Industries Ltd would be extended by three months to October. Israel's Teva and Allergan also agreed to reduce the cash consideration to be paid by $221 million and added Actonel and Carafate to the list of excluded products, Allergan said in a regulatory filing on...

  • Stocks to Watch: July 13, 2016

    Valeant, Fiat Chrysler and Amazon are making headlines this morning before the opening bell.

  • A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and...

  • Cramer's Mad Dash: This drug could be huge

    Jim Cramer explains why he is keeping an eye on shares of Sage Therapeutics.